Seroba Life Sciences

News, insights, analysis and data

← Back to Seroba Life Sciences profile

Seroba Life Sciences related stories

All articles and analysis

  • Side Letter: Brookfield's $15bn potential; Level 20's chair; ESG's lucrative talent war
    Private Equity News & AnalysisPEI Staff- 25 November 2021

    Brookfield is upping the stakes with its latest private equity flagship. Plus: industry non-profit Level 20 has appointed a new chair and in-demand ESG specialists are making seven-figure salaries. Here's today's brief, for our valued subscribers only.

  • Coave Therapeutics closes Series B
    News BriefsIris Dorbian- 21 July 2021

    Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.

  • Fusion Pharmaceuticals goes public, expects to raise $212m
    News BriefsIris Dorbian- 26 June 2020

    Fusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share.

  • VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report
    News BriefsVCJ Staff- 22 June 2020

    Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.

  • Shorla Pharma Limited nabs $8.3m
    News BriefsIris Dorbian- 3 June 2020

    Shorla Pharma Limited, an Irish specialty pharmaceutical company, has closed $8.3 million in financing.

  • Canadian VC landscape grew by 3x in 6 years
    Deals & ExitsRebecca Szkutak- 11 March 2020

    The North American market saw more than C$6.2 billion flow into the region last year.

  • Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln
    Kirk Falconer- 18 April 2019

    After nine straight years of growth, Canada’s venture capital market showed no signs of slowing down in early 2019. The top 10 first-quarter VC financings drew $667 million from VC funds. While that’s down 28 percent from the $923 million raised by the top 10 deals a year earlier, it exceeds first-quarter results in other recent years. The estimate is based on PE Hub Canada’s list of the largest rounds announced from January through March, supplemented by preliminary data from Refinitiv. It suggests that despite increasing market uncertainty, trends in early 2019 reflect many of the same factors that drove soaring Canadian VC investment activity last year.

  • Fusion Pharmaceuticals racks up $105 mln Series B
    Iris Dorbian- 3 April 2019

    Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised $105 million in Series B financing. Varian and OrbiMed led the round with participation from other investors that included Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Healthcap, Adams Street Partners, Johnson & Johnson Innovation – JJDC Inc, TPG Biotech, Seroba Life Sciences, Genesys Capital and FACIT. In conjunction with the funding, Deepak Khuntia, senior vice president and chief medical officer at Varian, Chau Q. Khuong, a partner at OrbiMed and Heather Preston, a managing director at Pivotal bioVenture Partners, will join Fusion’s board of directors.

  • Radiotherapeutics pioneer Fusion lands $140 mln in Series B round
    Kirk Falconer- 2 April 2019

    Fusion Pharmaceuticals, a cancer radiotherapeutics specialist, raised $140 million (US$105 million) in a Series B financing, one of the largest Canadian biotech deals on record. Varian Medical Systems, a Silicon Valley oncology business, co-led the round with New York healthcare investment giant OrbiMed. They were joined by new and existing investors, including Canadian life sciences venture firm Genesys Capital. Fusion's platform uses technology to link targeting molecules with short-path alpha medical isotopes to effectively kill cancer cells. “It’s essentially a smart bomb for cancer,” Genesys Managing Director Damian Lamb told PE Hub Canada.